ZYUS Life Sciences (TSE:ZYUS) has released an update.
ZYUS Life Sciences Corporation, a Canadian life sciences firm, has secured a CAD$1,000,000 unsecured loan from an independent director to bolster its working capital. The loan, with a 12% annual interest rate, is due by April 2025 but can be repaid earlier if the company raises at least $10 million through equity offerings. This financial move is expected to support ZYUS in its mission to develop non-opioid pain management therapies.
For further insights into TSE:ZYUS stock, check out TipRanks’ Stock Analysis page.
